Following is a cumulative list of Hoosier Cancer Research Network publications in esophageal cancer and gastric cancer.

Manuscripts and Journal Articles

• C Beccera, N Hanna, A McCollum, N Bechar, R Timmerman, M DiMaio, K Kesler, M Yu, T Yan, H Choy. A phase II study with cetuximab and radiation therapy for patients with surgically resectable esophageal and GEJ junction carcinomas: Hoosier Oncology Group GI05-92. J Thorac Oncol 2013 Nov;8(11):1425-9. doi: 10.1097/JTO.0b013e3182a46c3b PMID: 24084441.
• JM Schmitt, SR Sommers, W Fisher, R Ansari, E Robin, K Koneru, J McClean, Z Liu, N Hanna. Sunitinib plus paclitaxel in patients with advanced esophageal cancer: a phase II study from the Hoosier Oncology Group: GI06-112. J Thorac Oncol, 2012; 7: 760-763.
• P Mantravadi, N Fineberg, R Ansari, E Fox, P Helft, K Kesler, N Hanna, L Einhorn, C Stoner, R Govindan. A Phase II Study of Cisplatin, 5-Fluorouracil (5-FU), Radiation (RT) and Celecoxib in Patients with Resectable Esophageal Cancer (EC): Preliminary Results from the Hoosier Oncology Group: GI00-16. Supplement Oncology News International, October 2003.
• R Govindan, H McLeod, P Mantravadi, N Fineberg, P Helft, K Kesler, N Hanna, C Stoner, R Ansari, E Fox. Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. (GI00-16) Oncology (Williston Park). 2004 Dec;18(14 Suppl 14):18-21.

Abstracts, Posters, and Presentations

• MS Lee, J Chao, MF Mulcahy, PM Kasi, AT Alistar, S Mukherjee, M Akce, DT Moore, CA Carlson, AJ McRee. Phase II study of avelumab and trastuzumab with FOLFOX chemotherapy in previously untreated HER2-amplified metastatic gastroesophageal adenocarcinoma: GI17-319. Presented as a poster at the American Association for Cancer Research (AACR) 2021 Annual Meeting. See abstract.
• H Mamdani, R Mehta, C Fountzilas, M Radovich, S Perkins, SI Jalal. A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination (HR) defective or loss of heterozygosity (LOH) high-metastatic esophageal/GEJ/proximal gastric adenocarcinoma: ESO17-325. Presented as Trials In Progress Poster at the 2020 Gastrointestinal Cancers Symposium, January 23, 2020. J Clin Oncol 38, 2020 (suppl 4; abstr TPS472). See abstract.
• JM Schmitt, SR Sommers, W Fisher, R Ansari, E Robin, K Koneru, J McClean, Z Liu, N Hanna. Sunitinib plus Paclitaxel in patients with advanced esophageal cancer: a phase II study from the Hoosier Oncology Group: GI06-112. Accepted as abstract at the ASCO Annual Meeting, June 4-8 2011, Chicago, IL. J Clin Oncol 29: 2011 (suppl; abstr e14661).
• AK Agarwala, N Hanna, A McCollum, N Bechar, M DiMaio, M Yu, Y Tong, CR Beccera, H Choy. Pre-operative Cetuximab and Radiation (XRT) for Patients (pts) with Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas: A Pilot Study from the Hoosier Oncology Group (HOG) and the University of Texas-Southwestern: GI05-92. Accepted to the general poster session at the ASCO annual meeting May 29-June 2, 2009, Orlando, FL. J Clin Oncol 27:15s, 2009 (suppl; abstr 4557).
• MM Sgroi, N Hanna, A McCollum, N Bechar, M DiMaio, Z Hammoud, M Yu, H Choy, C Beccera. Pre-Operative Cetuximab and Radiation (XRT) for Patients (pts) with Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas: A Pilot Study from the Hoosier Oncology Group and the University of Texas-Southwestern: GI05-92. Accepted to the general poster session at the ASCO Annual Meeting, May 30-June 3, 2008, Chicago, IL.
• R Govindan, N Fineberg, H McLeod, K Kesler, N Hanna, C Stoner, J Vinson, R Mantravadi, L Einhorn. A Phase II Study of Cisplatin, 5-Fluorouracil (5-FU), Radiation (RT) and Celecoxib in Patients with Resectable Esophageal Cancer (EC): Hoosier Oncology Group GI00-16. Accepted to the general poster session at the ASCO annual meeting June 5-8, 2004, New Orleans, LA.
• P Mantravadi, N Fineberg, R Ansari, E Fox, P Helft, K Kesler, N Hanna, L Einhorn, C Stoner, R Govindan. A Phase II Study of Cisplatin, 5-Fluorouracil (5-FU), Radiation (RT) and Celecoxib in Patients with Resectable Esophageal Cancer (EC): Preliminary Results from the Hoosier Oncology Group: GI00-16. Poster presentation at the ASCO annual meeting May 31-June 3, 2003, Chicago, IL.